Springhill Fund Asset Management (HK) Co Ltd
CIK 1911270 · View on SEC EDGAR ↗
- Portfolio value
- $20.9M
- Positions
- 19
- As of
- March 31, 2025 Data as of Q1 2025
Portfolio value QoQ: -66.1% 13F does not disclose cash
- Top 10 holdings weight
- 82.88%
- Top 25 holdings weight
- 100.00%
- Positions above 1%
- 18
- Effective number of positions
- 10.9
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q1 2025: 32.66% Est. buys $13,461,133 · sells $57,165,711
- New positions
- 13
- Increased
- 2
- Decreased
- 4
- Closed
- 11
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
Performance vs S&P 500
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 100.0% · Options excluded: 0.0%
Sector breakdown
Full portfolio 19 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| VRNA Verona Pharma plc - American Depositary Shares | $4,031,552 | 19.32% | 63,499 | $-2,258,839 | Down ×1 | ||
| SMMT Summit Therapeutics Inc. - Common Stock | $2,397,882 | 11.49% | 124,307 | Up ×1 | |||
| JANX Janux Therapeutics, Inc. - Common Stock | $2,119,500 | 10.16% | 78,500 | $534,716 | Up ×1 | ||
| REGN Regeneron Pharmaceuticals, Inc. - Common Stock | $1,648,998 | 7.90% | 2,600 | Up ×1 | |||
| NBIX Neurocrine Biosciences, Inc. - Common Stock | $1,505,487 | 7.21% | 13,612 | Up ×1 | |||
| INSM Insmed Incorporated - Common Stock | $1,464,158 | 7.02% | 19,192 | $-3,334,122 | Down ×1 | ||
| SLNO Soleno Therapeutics, Inc. - Common Stock | $1,418,854 | 6.80% | 19,858 | $1,338,259 | Up ×1 | ||
| JAZZ Jazz Pharmaceuticals plc - Ordinary Shares | $1,223,250 | 5.86% | 9,853 | Up ×1 | |||
| AKRO Akero Therapeutics, Inc. - Common Stock | $806,564 | 3.87% | 19,925 | $-3,399,820 | Down ×1 | ||
| ARGX argenx SE - American Depositary Shares | $678,277 | 3.25% | 1,146 | Up ×1 | |||
| LLY Eli Lilly and Company Common Stock | $673,943 | 3.23% | 816 | Up ×1 | |||
| PTGX Protagonist Therapeutics, Inc. - Common Stock | $621,861 | 2.98% | 12,859 | Up ×1 | |||
| TGTX TG Therapeutics, Inc. - Common Stock | $532,305 | 2.55% | 13,500 | Up ×1 | |||
| TARS Tarsus Pharmaceuticals, Inc. - Common Stock | $363,494 | 1.74% | 7,076 | Up ×1 | |||
| ASND Ascendis Pharma A/S - American Depositary Shares | $338,684 | 1.62% | 2,173 | Up ×1 | |||
| RYTM Rhythm Pharmaceuticals, Inc. - Common Stock | $332,493 | 1.59% | 6,277 | Up ×1 | |||
| BNTX BioNTech SE - American Depositary Shares | $273,180 | 1.31% | 3,000 | Up ×1 | |||
| SWTX | $260,235 | 1.25% | 5,897 | Up ×1 | |||
| COGT Cogent Biosciences, Inc. - Common Stock | $176,651 | 0.85% | 29,491 | $-4,102,070 | Down ×1 | ||
| No matches | |||||||
Biggest new bets
New positions opened this quarter, largest first.
| Security | Value | Shares | % of portfolio |
|---|---|---|---|
| SMMT | $2,397,882 | 124,307 | 11.49% |
| REGN | $1,648,998 | 2,600 | 7.90% |
| NBIX | $1,505,487 | 13,612 | 7.21% |
| JAZZ | $1,223,250 | 9,853 | 5.86% |
| ARGX | $678,277 | 1,146 | 3.25% |
| LLY | $673,943 | 816 | 3.23% |
| PTGX | $621,861 | 12,859 | 2.98% |
| TGTX | $532,305 | 13,500 | 2.55% |
| TARS | $363,494 | 7,076 | 1.74% |
| ASND | $338,684 | 2,173 | 1.62% |
| RYTM | $332,493 | 6,277 | 1.59% |
| BNTX | $273,180 | 3,000 | 1.31% |
| SWTX | $260,235 | 5,897 | 1.25% |
Top movers (QoQ)
| Security | Action | Shares Δ | Value Δ |
|---|---|---|---|
| INSM | Trimmed | -50K | -$3.3M |
| VRNA | Trimmed | -72K | -$2.3M |
| JANX | Bought more | +49K | +$535K |
3 positions hidden (data completeness check)
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| LEGN | March 31, 2025 | 190,800 | $6,208,632 | -35.8% |
| CYTK | March 31, 2025 | 130,735 | $6,149,774 | 92.8% |
| AZN | March 31, 2025 | 76,500 | $5,012,280 | 125.2% |
| VERA | March 31, 2025 | 109,400 | $4,626,526 | 31.8% |
| MRUS | March 31, 2025 | 83,800 | $3,523,790 | No longer tracked |
| CGEM | March 31, 2025 | 276,400 | $3,366,552 | 187.5% |
| DYN | March 31, 2025 | 131,200 | $3,091,072 | 152.3% |
| NRIX | March 31, 2025 | 160,500 | $3,023,820 | 127.9% |
| DRUG | March 31, 2025 | 60,648 | $2,184,541 | 117.4% |
| BCYC | March 31, 2025 | 116,400 | $1,629,600 | -48.6% |
| ABVX | March 31, 2025 | 207,600 | $1,519,632 | 1811.2% |